Xilio Therapeutics, Inc. develops masked immuno-oncology therapies for people living with cancer. Company news centers on its proprietary masking technology, which is designed to localize anti-tumor activity within the tumor microenvironment, and on pipeline updates for masked biologics and multi-specific I-O molecules.
Recurring developments include preclinical data for programs such as XTX601, a masked T cell engager targeting CLDN18.2, updates on XTX501, a bispecific PD-1 / masked IL-2 program, and disclosures involving masked T cell engager programs targeting PSMA and STEAP1. News also covers financial results, scientific conference presentations, inducement equity grants, board composition, and capital-structure actions.
Xilio Therapeutics, Inc. (Nasdaq: XLO) announced key leadership changes on June 16, 2022. Martin Huber, M.D., is promoted to president while continuing as head of R&D. Paul Clancy is elected chair of the board, succeeding Dan Lynch, who will serve as a strategic advisor. Clancy has been part of the board since July 2020 and brings extensive financial management experience. Additionally, Robert Ross, M.D., joins the board, enhancing Xilio’s oncology expertise. These leadership changes aim to improve Xilio’s strategic direction and advance its tumor-selective immuno-oncology programs.
Xilio Therapeutics, a biotechnology company focused on tumor-selective immuno-oncology therapies, announced that Dr. Marty Huber will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 2:30 p.m. ET. A live webcast will be available on the company’s website, with a replay accessible for 30 days. Xilio is advancing its proprietary GPS platform to create targeted therapies like XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-selective IL-2, aiming to enhance anti-tumor activity while minimizing systemic effects.
Xilio Therapeutics, Inc. (Nasdaq: XLO) has appointed Stacey Davis as its new chief business officer to enhance corporate and business development strategies for future growth. With over 25 years in the life sciences sector, Davis comes from Novartis Oncology and has a proven track record in oncology and immunology. Xilio is advancing its pipeline of tumor-selective immunotherapies, with clinical data readouts expected later this year. The company aims to improve cancer treatment outcomes through its innovative geographically precise solutions (GPS) platform.
Xilio Therapeutics (Nasdaq: XLO) announced pipeline and financial highlights for Q1 2022, showcasing ongoing clinical trials for XTX202 and XTX101, with preliminary data expected later in 2022.
The company maintains a strong financial position with $177 million in cash, expected to fund operations into H1 2024. R&D expenses rose to $14.9 million, while net loss was $21.4 million for the quarter. Future prospects include submitting an IND for XTX301, a tumor-selective IL-12, later this year.
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology firm focused on tumor-selective immuno-oncology therapies, will be presenting at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 8:00 a.m. ET. Dr. Marty Huber, president of research and development and chief medical officer, will lead the presentation. A live webcast will be accessible on the company’s website, with an archived replay available for 30 days.
The company utilizes its proprietary GPS platform to innovate cytokines and biologics aimed at localized anti-tumor activity.
Xilio Therapeutics, Inc. (Nasdaq: XLO) reported significant progress in its clinical pipeline and financial results for 2021. The company has $198.1 million in cash, ensuring operational continuity into 2024. Key developments include anticipated initial Phase 1 data readouts for XTX101 and XTX202 in 2022, along with plans to submit an IND for XTX301. Research and Development (R&D) expenses rose to $51.2 million for 2021, primarily due to increased personnel costs. Xilio ended the year with a net loss of $75.8 million.
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology firm focusing on tumor-selective immuno-oncology therapies, announced that CEO René Russo will participate in the "Novel IO Panel" at the Cowen 42nd Annual Healthcare Conference on March 7, 2022, at 10:30 a.m. ET. The event will be available via live webcast on the company’s website, with a replay accessible for 30 days post-presentation. Xilio aims to enhance cancer treatment using its proprietary GPS platform to create targeted biologics, including several promising therapeutic candidates.
Xilio Therapeutics, Inc. (Nasdaq: XLO) will host a virtual fireside chat at the Guggenheim 4th Annual Oncology Day on February 10, 2022, at 8:30 a.m. ET. The event will feature CEO René Russo and CMO Marty Huber discussing the company’s tumor-selective immuno-oncology therapies. A live webcast will be accessible via Xilio’s website, and a replay will be available for 30 days post-event. Xilio is dedicated to developing innovative cancer treatments utilizing its proprietary GPS platform, focusing on tumor-localized biologics aimed at enhancing anti-tumor activity.
Xilio Therapeutics (Nasdaq: XLO) announced the first patient has been dosed in its Phase 1/2 clinical trial for XTX202, an innovative IL-2 therapy aimed at treating solid tumors. Designed to target the tumor microenvironment (TME), XTX202 aims to enhance anti-tumor effects while minimizing toxicity compared to existing IL-2 therapies. The trial will assess safety, tolerability, and effectiveness in patients with advanced solid tumors, setting the stage for further investigations in larger, more diverse cohorts.
Xilio Therapeutics, Inc. (Nasdaq: XLO) appointed Dr. Yuan Xu to its board of directors. Dr. Xu brings over 25 years of experience in the biopharmaceutical industry, having previously served as CEO at Legend Biotech and senior VP at Merck. Her leadership is expected to be crucial as Xilio advances its tumor-selective immuno-oncology therapies, with data readouts for two programs anticipated in 2022. Dr. Xu emphasized the importance of Xilio’s mission to develop therapies that minimize toxicity while maximizing effectiveness, including product candidates XTX101 and XTX202.